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ABSTRACT
We investigated a panel of 14 compounds belonging to the monothiocarbamate (MTC) and dithiocarba-
mate (DTC) series against the b-carbonic anhydrase 3 (b-CA3) of Mycobacterium tuberculosis (Mtb). We
also evaluated all compounds for toxicity using 1–5-day post fertilisation zebrafish embryos. 11 out of the
14 investigated derivatives showed effective nanomolar or submicromolar in vitro inhibition against the
b-CA3 (KIs 2.4–812.0 nM), and among them four DTCs of the series (8–10 and 12) showed very significant
inhibition potencies with KIs between 2.4 and 43nM. Out of 14 compounds screened for toxicity and
safety 9 compounds showed no adverse phenotypic effects on the developing zebrafish larvae at five
days of exposure. The results of in vitro inhibition and the toxicological evaluation of our study suggest
that 5 compounds are suitable for further in vivo preclinical characterisation in zebrafish model.
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Introduction
Mtb is a highly infectious microbial species that causes tubercu-
losis (TB) in humans. The latest World Health Organisation report
on infectious diseases estimated that annually, 10 million people
develop TB and 1.6 million die from the disease1. Quite worry-
ingly, the same study reported >550 000 infections to be caused
by rifampin-resistant strains that are unresponsive to this first-line
drug against Mtb. Among these strains, 80% were multidrug-
resistant (MDR-TB)1. Therefore, there is an urgent need for antibi-
otics targeting novel physiological pathways of Mtb2–4.
Mycobacteria encode for at least three zinc-containing metal-
loenzyme carbonic anhydrases (CAs, EC 4.2.1.1) that belong to the
b-CA gene family1,2. Since the primary function of b-CAs in myco-
bacteria is to reversibly catalyse the hydration of CO2 to generate
HCO3
 and Hþ ions5,6, such enzymes are involved in a multitude
of physiological processes closely related to pH homeostasis, bio-
synthetic processes as well as adaption to the environments3,7–10.
In addition, mycobacterial b-CAs have been shown to be essential
for the transport of extracellular DNA (eDNA)11. It was also
reported that the administration of the non-selective CA Inhibitor
(CAI) ethoxzolamide (EZA) reduced transport of eDNA and
affected the formation of biofilms in non-tuberculous mycobacte-
ria (NTM)11. Another study conducted on Mycobacterium tubercu-
losis (Mtb) strains, demonstrated that EZA inhibited the two-
component PhoPR regulon as well as the Esx-1 protein secretion
system, which are fundamental for the virulence of the bacter-
ium12. EZA also showed efficacy in infected macrophages and
mice suggesting that b-CAs perform very important roles in
mycobacterial infections12, and hence present themselves as
potential drug targets. The three Mtb b-CAs (i.e. b-CA1, b-CA2 and
b-CA3) are encoded by Rv1284, Rv3588c and Rv3273 genes,
respectively8,13–16. Among the compounds tested in vitro for their
inhibition properties against such enzymes are the classical CAIs
of the sulphonamide type17,18, and the recently reported dithio-
and monothiocarbamates19,20 (DTCs and MTCs) whose general
structures are shown in Figure 1.
Both DTCs and MTCs have been explored, with good out-
comes, against several CAs from pathogens expressing a-, b-, and
d-CA enzymes19–23. A study conducted in our laboratory showed
that a DTC-based compound (i.e. derivative 12 in this study) not
only effectively inhibited the b-CAs of Mtb but also impaired the
growth of Mycobacterium marinum, a close relative of Mtb, in
zebrafish larvae2. The data obtained by means of in vitro and
in vivo experiments involving DTCs and MTCs encouraged us to
further investigate similar compounds against the Mtb b-CA3 with
the aim to find new potential inhibitors targeting mycobacter-
ial b-CAs2,21.
Materials and methods
Chemistry
Compounds 1-14 considered in this manuscript were synthesised
according to the procedures previously reported by some of us,
and they were properly characterised by means of 1H-NMR, 13 C-
NMR, and mass spectra analysis24–27.
CONTACT Ashok Aspatwar ashok.aspatwar@tuni.fi Faculty of Medicine and Health Technology, Tampere University, Arvo Ylpon katu 34, Tampere,
33014 Finland
 2019 The Author(s). Published by Informa UK Limited, trading as Taylor & Francis Group.
This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use,
distribution, and reproduction in any medium, provided the original work is properly cited.
JOURNAL OF ENZYME INHIBITION AND MEDICINAL CHEMISTRY
2020, VOL. 35, NO. 1, 65–71
https://doi.org/10.1080/14756366.2019.1683007
In vitro carbonic anhydrase inhibition assay
The CA-catalyzed CO2 hydration activity was assayed on an
Applied Photophysics stopped-flow instrument using phenol red
(at a concentration of 0.2mM) as a pH indicator with 20mM
Hepes (pH 7.5) as the buffer, 20mM Na2SO4, and following the ini-
tial rates of the CA-catalyzed CO2 hydration reaction for a period
of 10 100 s and working at the maximum absorbance of
557 nm28–30. The CO2 concentrations ranged from 1.7 to 17mM.
For each inhibitor six traces of the initial 5 10% of the reaction
have been used in order to determine the initial velocity. The
uncatalyzed reaction rates were determined in the same manner
and subtracted from the total observed rates. Stock solutions of
inhibitor (0.1mM) were prepared in distilled water, and dilutions
up to 0.01 nM were prepared. Solutions containing the inhibitor
and enzyme were preincubated for 15min at room temperature
prior to assay in order to allow the formation of the E I complex.
The inhibition constants were obtained as nonlinear least-squares
protocols using PRISM 328–30 and are the mean from at least three
different measurements. All hCAs were recombinant ones and
were obtained in house28–30.
Toxicity evaluation
Inhibitors
Compounds 1–14 were either dissolved in Embryonic medium
[5.0mM NaCl, 0.17mM KCl, 0.33mM CaCl2, 0.33mM MgSO4, and
0.1% w/v Methylene Blue (Sigma-Aldrich, Germany)] or in dimethyl
sulfoxide (DMSO) (Sigma-Aldrich, St. Louis, MO) to prepare
100mM stock solutions. Before the start of each experiment, the
series of dilutions were made from the above stock in the embry-
onic medium.
Maintenance of zebrafish
The wild type adult zebrafish (AB strains) were maintained at
28.5 C. 3–5 pairs of male and female fish were moved to breed-
ing tanks overnight31. Next morning, 1–2-h post fertilisation (hpf),
embryos were collected in a sieve and rinsed with embryonic
medium, and the collected embryos were maintained in an incu-
bator at 28.5 C overnight31. The toxicity evaluation studies of the
inhibitors were initiated with fish embryos 24-hpf. All the fish
experiments were performed at the zebrafish core facility of
Tampere University according to the protocol used in our
laboratory32.
Ethical statement
The research unit at Tampere University has an established zebra-
fish core facility authorised by the National Animal Experiment
Board (ESAVI/7975/04.10.05/2016). The experiments using develop-
ing zebrafish embryos were performed according to the Provincial
Government of Eastern Finland Province Social and Health
Department Tampere Regional Service Unit protocol # LSLH-
2007–7254/Ym-23. Care was taken to ameliorate suffering by
euthanizing the 5 dpf larvae by prolonged immersion in a petri
dish containing an overdose of Tricaine (Sigma-Aldrich, St. Louis,
MO) before fixing in buffered formaldehyde for histochem-
ical analysis.
Determination of median lethal concentration 50 (LC50)
The LC50 values for all the MTC and DTC compounds were deter-
mined using 24-hpf embryos with 10–12 different concentrations
for each compound. For every concentration of the inhibitor, we
used 30 24-hpf embryos31,32. For each compound, the fish were
exposed to different concentrations of the inhibitors rangeing
from 5 lM to 2.5mM. Dose response curve (DRC) was calculated
using DRM of the DRC R package33. The control group larvae con-
stituted an equal number of larvae not treated with any inhibitor
compound and the larvae that were treated with 1% of DMSO.
Toxicological evaluation studies were performed in 24-well plates
(Corning V R Co-star V R cell culture plates). One or two 24-hpf
embryos in were placed per well in 1mL of embryonic medium
containing a diluted inhibitor. A minimum of three sets of experi-
ments were carried out for each inhibitor. Mortality of the larvae
was checked every 24 h until 5 days after exposure to
the inhibitors.
Phenotypic analysis of control and inhibitor treated larvae
After exposure to the inhibitors, we evaluated the effects of these
inhibitors on the zebrafish larvae and analysed eight phenotypic
parameters: (1) mortality, (2) hatching, (3) oedema, (4) swimming
pattern, (5) yolk sack utilisation, (6) heartbeat, (7) body shape, and
(8) swim bladder development. The images of the developing lar-
vae were taken using a Lumar V1.12 microscope attached to a
camera (Carl Zeiss MicroImaging GmbH, G€ottingen, Germany). The
images were analysed with AxioVision software versions 4.7 and
4.8 as described in our standard protocol for assessment of tox-
icity and safety of the chemical compounds32.
Swim pattern analysis
The swim pattern of the zebrafish larvae was studied after 5 days
of exposure to these inhibitors. For the analyses of swim pattern,
about 10–15 zebrafish larvae were placed in a 35mm X 15mm
petri dish containing embryonic medium and the larvae were
allowed to settle in the petri dish for 1min. The movement of the
zebrafish larvae was observed under the microscope for 1min.
The swim patterns were compared with the control group zebra-
fish larvae that were not treated with any inhibitor.
Histological studies
The histochemical analyses were done to assess the effect of
inhibitors on the morphology of tissues of the larvae that were
treated with different concentrations of inhibitors. The control
group larvae were treated with embryonic medium alone or with
1% DMSO in embryonic medium. After 5 days of treatment the lar-
vae were washed with phosphate buffered saline (PBS) and
immersed in excess amounts of Tricaine to anaesthetize them. The
Figure 1. General structures of dithiocarbamates (DTC) and monothiocarba-
mates (MTC).
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larvae were transferred to a 1.5mL microcentrifuge tube and fixed
in buffered formaldehyde (4% formaldehyde solution, pH 6.9) in
PBS for 3 h at room temperature or overnight at 4 C. After the fix-
ation, the larvae were transferred to 70% ethanol and stored at
4 C before embedding in paraffin. The samples were then sec-
tioned into 5 lm thin slices for the histochemical staining. The
sections were deparaffinized in xylene, rehydrated in an alcohol
series, and stained with Mayer’s Haematoxylin and Eosin Y (both
from Sigma-Aldrich). After dehydration, the slides were mounted
with EntellanVR Neu (Merck; Darmstadt, Germany). The slides con-
taining the tissues were examined for morphological changes and
photographed using a Nikon Microphot microscope (Nikon
Microphot- FXA, Japan). All the procedures were carried out at
room temperature unless stated otherwise.
Results and discussion
Chemistry
The main structural differences among the compounds tested in
this study are related to the metal binding moieties of CAs. The
compounds included both monothiocarbamates (MTCs) 1–7 and
dithiocarbamates (DTCs) 8–14 (Figure 2).
In order to efficiently explore the inhibition potencies of the
MTC and DTC binding moieties on Mtb b-CA3, we decided to
consider small size and lined-shaped scaffolds lacking any bulky
substitution. Such an approach was also justified by the narrower
size of the b CA’s cavities when compared to the a ones34. As
reported in Figure 2 almost all compounds responded to such a
rule and the only exceptions were the 3-carboxy substituted
piperazine 13 and the bicyclo[2.2.2]octan-2-amine 14.
CA inhibition
Compounds 1–14 were tested in vitro for their inhibitory proper-
ties against the Mtb b-CA3 and the data are reported in Table 1.
The kinetic data reported in Table 1 clearly showed that
among the MTCs tested the derivative 4 was the most potent
compound in inhibiting the Mtb b-CA3 with a KI value of 83.3 nM,
followed by the phenylethyl 5 (KI 93.0 nM) and its 3,4-dimethoxy-
phenylethyl derivative 7 (KI 97.9 nM), and thus slightly more
potent than the reference CAI AAZ (KI 104 nM). All the other
remaining MTCs (i.e. 1–3 and 6) were high nanomolar range
inhibitors of the b-CA3 with KI values spanning between 558.6
and 812.0 nM. Interestingly MTCs 4, 5 and 7 were ineffective
inhibitors of the hCA I (KIs >2000 for compounds 4 and 5, 891 nM
for 7 respectively). Conversely, compounds 4, 5 and 7 showed
good inhibition data on hCA II being up to 3.7 fold more potent
(KIs of 43.6, 43.7 and 26.7 nM, respectively). An analogous kinetic
trend was observed for the remaining MTCs 1, 3 and 6 which
were quite effective inhibitors of the hCA II over the hCA I iso-
form. The only exception is represented by the MTC based
Figure 2. Chemical structures of MTCs 1-7 and DTCs 8-14.
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morpholine 2 which showed high nanomolar KI value on the hCA
I (KI 569 nM) and no effects on the hCA II isoform (KI >2000).
As for the isosteric DTC derivatives 8–14 a rather different kin-
etic profile was observed. For instance, the morpholine DTC 9 was
the most potent inhibitor within the series against Mtb b-CA3 (KI
of 2.4 nM) and quite interestingly it was 311.5 fold more potent
when compared to its MTC analogous compound 2 (see Table 1).
A similar kinetic trend was reported also for the bis-piperazine
derivative DTC 10 in comparison to its MTC counterpart 3 with
the former being 101.5 fold more potent on the b-CA3 (KIs of 8.0
and 812.0 nM, respectively). An opposite kinetic trend was
reported for the DTC 11 which was ineffective on the b-CA3,
whereas its MTC derivative 6 was a high nanomolar inhibitor (KIs
of >2000 and 780.7 nM, respectively). Among the DTCs reported
in this study, the N-methylpiperazine 12 was the second most
potent inhibitor against the b-CA3 just after the morpholine
derivative 9 (KI of 2.6 and 2.4 nM, respectively). The structural dif-
ferences between 9 and 12 (i.e. an oxygen and an N-methyl moi-
ety at 4-position of the scaffold, respectively) did not affect the
inhibition potencies against the b-CA3, whereas they proved cru-
cial for the inhibition of the hCAs I and II. As reported in Table 1
the morpholine derivative 9 was a sub-nanomolar inhibitor of the
hCAs reported (KIs of 0.88 and 0.95 nM for the hCA I and II,
respectively), whereas the N-methyl piperazine 12 was a medium
potency inhibitor (KIs of 33.5 and 33.5 nM, respectively), that
makes the latter more selective against the b-CA3 isoform.
Interestingly, the substitution of the alkyl ring in 9 or 12 with a
bis-alkyl chain, as in compound 8, or its modification to produce
13 and 14, resulted in detrimental reductions for the inhibition
potency against the b-CA3 (see Table 1).
Evaluation of safety and toxicity
Determination of inhibitor LC50 concentrations
The lethal concentrations of the MTC and DTC 1–14 inhibitors
were tested on developing zebrafish embryos. The lowest concen-
tration that caused death of half of the embryos was reported for
the DTC 8 (i.e. LD50 2 lM), which was therefore considered highly
toxic and not suitable for further testing in our studies. The LC50
values of all the compounds are shown in Table 2.
Phenotypic analyses of zebrafish larvae treated with inhibi-
tor compounds
To assess the toxic effects of the inhibitors on 5-day-old zebrafish
during development after 4-day exposure to the compounds, we
analysed seven observable phenotypic parameters (Table 3) using
a stereo microscope and recorded the observations for each
group. The zebrafish treated with CAIs were compared with the
control groups not treated with any compound or with 1% DMSO.
The maximum concentration of each compound that does not
induce any phenotypic changes in the larvae at 5 days of exposure
was considered as safe (Table 2) and can be used for in vivo
inhibition of M. marinum in zebrafish larvae2. The images in
Figure 3 show representative larvae exposed to MTCs and DTCs
in which no apparent phenotypic defects were observed except
the compound 8 that showed defects in the development of
swim bladder (Figure 3, arrow). DTC 12 that inhibited Mtb b-CAs
in vitro efficiently in our earlier studies36, showed similar results
and was used for in vivo inhibition of M. marinum in zebra-
fish studies1.
Further analyses of the embryos to assess the toxicity of com-
pounds at the concentrations that are considered as safe (Table 2)
on the observable phenotypic parameters showed that some of
the compounds had no significant effects on any of the parame-
ters assessed (Table 3). The compounds that were considered
toxic, showed different level of toxicity by inducing high mortality,
Table 1. Inhibition data of Mtb b-CA3 and human CA isoforms hCA I and II for
compounds 1–14, determined by the stopped-flow CO2 hydrase assay
35, using
acetazolamide (AAZ) as a standard drug.
KI (nM)
a
Compounds Mtb b-CA3 hCA I hCA II
1 558.6 >200026 46.726
2 747.6 56926 >200026
3 812.0 87626 22.426
4 83.3 >200026 43.626
5 93.0 >200026 43.726
6 780.7 94926 45.926
7 97.9 89126 26.726
8 43.0 0.9725 0.9525
9 2.4 0.8825 0.9525
10 8.0 12.625 0.9225
11 >2000 41527 67.227
12 2.6 33.525 33.025
13 >2000 49627 80.527
14 >2000 49427 48.727
AAZ 104 250.0 12.0
aMean from 3 different assays, by a stopped flow technique (errors were in the
range of ± 5–10% of the reported values).
Table 2. LC50 of the CAIs 1–14.
Compounds LC50 dose In vivo studies (lM)
a
1 1mM 400
2 1mM 125
3 2mM 500
4 125lM 35
5 1mM 400
6 2mM 500
7 2mM 500
8 2lM 1
9 125lM 18
10 2mM 500
11 1mM 250
12 600lM 300b
13 1mM 500
14 25lM 5
aThe concentrations do not induce any phenotypic defects in zebrafish larvae at
5 days of exposure and safe for inhibition studies of M. marinum in zebrafish2.
bThe compound 12 (Fc14-584b) is screened for toxicity and for in vivo inhibition
studies as reported earlier2.
Table 3. Effect of inhibitors on phenotypic parameters of the larvae 5 days of
after exposurea,b.
Compounds Hatching Oedema Heartbeat Yolk sac Body shape Swim bladder
1 100 0 0 0 6 0
2 100 5 4 5 5 0
3 100 0 0 0 2 0
4 100 0 3 0 0 0
5 100 2 0 3 1 0
6 100 0.7 0 0 0.7 0.7
7 100 0 0 1 1 0
8 80 10 100 0 8 22
9 0 NA NA NA NA NA
10 100 0 0 0 0 0
11 100 0 0 0 0 0
12c NA NA NA NA NA NA2
13 100 2 0 2 4 0
14 100 12 7 8 10 14
NA: not applicable.
aThe parameters were assessed at LC50 at 5 day of exposure to the compounds.
bThe values shown are in percent of larvae.
cThe compound was screened for toxicity in our previous studies.
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problem with hatching, oedema, heartbeat, yolk sac utilisation,
body shape, and swim bladder development (Figure 3) as shown
in Table 3.
Histochemical analysis
We analysed the sections of the zebrafish that were exposed to
the inhibitors which did not have any significant effect on the
phenotypic parameters (Table 2) of the larvae at the end of 5 days
of exposure to the inhibitors. The histologically stained sections of
the inhibitor-treated larvae were compared with the stained sec-
tions of the control group larvae. None of the inhibitors showed
any morphological changes of tissues of the zebrafish larvae
exposed to the MTCs or DTCs (data not shown). The results of
the histological examination suggest that these inhibitors cause
no damage to the internal tissues at the concentrations tested
and can be used for further characterisation.
Swim pattern analysis of larvae exposed to the inhibitors
Zebrafish embryos are easily affected by chemical compounds
compared to adult zebrafish or other animal models and are
hence suitable model organisms for assessing the subtle toxic
effects of chemicals32,37. In this study, we further assessed the
subtle toxic effects of the inhibitors by analysing the swim pat-
terns of the larvae during exposure to the inhibitors at
concentration that are considered as safe shown in Table 2. The
swim pattern analysis showed that 11 out of 14 compounds
showed no abnormal or ataxic movement of the larvae that were
exposed to the inhibitors (data now shown). Therefore, most of
the compounds that efficiently inhibit Mtb b-CA3 show no or min-
imal toxicity at relevant concentrations and are thus safe for fur-
ther characterisation in vivo2,32 (Table 4).
Conclusions
In this study, we investigated a series of 14 CAIs belonging to the
MTC and DTC zinc binding moieties possessing a variety of scaf-
folds and intended as inhibitors of the b-CA3 from M. tuberculosis.
All compounds were investigated in vitro for their inhibition
potencies against Mtb b-CA3 and compared to the human hCA I
and II. The Mtb b-CA3 was efficiently inhibited by 11 of these
derivatives with KIs in the range of 2.4–812 nM. We evaluated
these compounds for their toxic effects on 1–5 dpf zebrafish lar-
vae. The toxicological studies showed that the compounds 1, 3,
5, 7, and 10 exhibited minimal toxicity and were considered as
safe for further characterisation in vivo. The results of the in vitro
inhibition and toxicological evaluation studies showed that 5 com-
pounds can be used for in vivo inhibition of the M. marinum
growth in zebrafish larvae for further preclinical characterisation.
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Figure 3. Images of zebrafish larvae treated with different inhibitors. The identification number of each compound is in parenthesis. The images of the zebrafish larvae
after 5 days of exposure to inhibitors that are considered safe for in vivo use to inhibit M. marinum growth in larvae2. The concentrations of the MTCs and DTCs shown
here are the highest ones generally not inducing phenotypic defects at the end of 5 days of exposure. For compound 8, even the lowest concentration used caused
the absence of swim bladder (arrow), suggesting that this compound is not suitable for further characterization2.
Table 4. The compounds that inhibit Mtb b-CA3 efficiently and show min-
imal toxicity.
Compounds KI (nM)
a Safe concentration (lM)b
1 558.6 400
3 812.0 500
5 93.0 400
7 97.9 500
10 8.0 500
aInhibition of b-CA3 in vitro.
bThe concentration that can be used for in vivo studies.
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